Literature DB >> 3126749

Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males.

R Sorva1, T Kuusi, M R Taskinen, J Perheentupa, E A Nikkilä.   

Abstract

We studied the effects of testosterone substitution on serum concentrations of lipids, lipoproteins, apoproteins and on the activity of hepatic lipase (HL) and lipoprotein lipase (LPL) in postheparin plasma and on the activity of LPL in adipose tissue (AT-LPL) in 13 male hypopituitary patients. The activities of LPL and HL in postheparin plasma were markedly increased by 1 week after a testosterone enanthate injection (P less than 0.001). The HL activity remained elevated (P less than 0.05) after 1 month's treatment, but the LPL activity declined to presubstitution levels. The prolonged substitution decreased serum apoproteins A-I and A-II (P less than 0.05). The changes of apo A-I and A-II correlated inversely with those of the free testosterone index (FTI) (r = -0.74, r = -0.67, P less than 0.05). Serum HDL-cholesterol level decreased slightly by 1 week and it correlated inversely with the increase in testosterone and the FTI (r = -0.67, r = -0.85, P less than 0.05). The results suggest that testosterone increases the activity of both lipolytic enzymes in postheparin plasma. The effect on HL appears to be more persistent than that on LPL. The data support a role for androgens in the regulation of serum lipoprotein and HDL-cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126749     DOI: 10.1016/0021-9150(88)90014-7

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  12 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 2.  Anabolic-androgenic steroid effects on endocrinology and lipid metabolism in athletes.

Authors:  M Alén; P Rahkila
Journal:  Sports Med       Date:  1988-12       Impact factor: 11.136

Review 3.  Testosterone supplementation and body composition: results from a meta-analysis of observational studies.

Authors:  G Corona; V A Giagulli; E Maseroli; L Vignozzi; A Aversa; M Zitzmann; F Saad; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-05-30       Impact factor: 4.256

Review 4.  Testosterone therapy in men: clinical and pharmacological perspectives.

Authors:  A Gambineri; R Pasquali
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

Review 5.  Age-related changes in male gonadal function. Implications for therapy.

Authors:  D Maas; A Jochen; B Lalande
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

Review 6.  Andropause. Testosterone replacement therapy for aging men.

Authors:  J Bain
Journal:  Can Fam Physician       Date:  2001-01       Impact factor: 3.275

7.  Effect of Selective Androgen Receptor Modulator on Cholesterol Efflux Capacity, Size, and Subspecies of HDL Particles.

Authors:  Wen Guo; Karol M Pencina; Jeremy D Furtado; Frank M Sacks; Tomas Vaisar; Ming Cheng; Allan D Sniderman; Stephanie T Page; Shalender Bhasin
Journal:  J Endocr Soc       Date:  2022-06-28

8.  Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life.

Authors:  C J Malkin; P J Pugh; P D Morris; K E Kerry; R D Jones; T H Jones; K S Channer
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

9.  Lipid metabolism in young males with hypotestosteronaemia and oligospermia prior to, during, and after treatment.

Authors:  M Hromadová; T Hácik; E Malatinský; A Sklovský; J Cervenakov; F Lábady
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

Review 10.  Testosterone for the aging male; current evidence and recommended practice.

Authors:  Roger D Stanworth; T Hugh Jones
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.